Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL294105

CCCCn1cc[n+](C)c1.O=S(=O)([O-])C(F)(F)F

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.58
HSP90AA1 P07900 2/20 0.58
KMT2A Q03164 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
APAF1 O14727 1/20 0.58
NPC1 O15118 1/20 0.58
PLA2G1B P04054 1/20 0.58
MAPT P10636 1/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
RAB9A P51151 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
ATG4B Q9Y4P1 1/20 0.58
KCNH2 Q12809 7/20 0.42
FDPS P14324 10/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL29390371 1.00 MEN1 (0.58) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL3615950 0.96 MEN1 (0.65) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL318471 0.95 MEN1 (0.52) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL318175 0.94 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL318767 0.94 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL514445 0.94 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL318764 0.94 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL318566 0.94 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL1331129 0.94 MEN1 (0.68) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Trifluoromethanesulfonic Acid SCHEMBL1293510 0.93 MEN1 (0.62) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099153-A1 DEVICE CAPABLE OF BONDING AND DEBONDING ON DEMAND TESA SE (DE) 2026-05-15 WO claimed
EP-4721970-A1 BONDED STRUCTURE COMPRISING AN ELECTROCHEMICALLY DEBONDABLE ADHESIVE LAYER Henkel AG & Co. KGaA (DE) 2026-04-08 EP claimed
US-20260088410-A1 ELECTRONICS ASSEMBLY HAVING ELECTROCHEMICALLY DEBONDABLE COMPONENTS HENKEL AG & CO KGAA (DE) 2026-03-26 US claimed
US-12540262-B2 Two component (2K) curable adhesive composition HENKEL AG & CO. KGAA (DE) 2026-02-03 US claimed
US-20250382408-A1 EPOXY-TERMINATED ISOCYANATE PREPOLYMERS, AND PROCESS FOR THE PREPARATION THEREOF BASF SE (DE) 2025-12-18 US claimed
WO-2025242379-A1 BONDED STRUCTURE COMPRISING AN ELECTROCHEMICALLY DEBONDABLE ADHESIVE FILM HENKEL AG & CO. KGAA (DE) 2025-11-27 WO claimed
US-12476286-B2 Rechargeable calcium battery SYRACUSE UNIVERSITY (US) 2025-11-18 US claimed
WO-2025228672-A1 TWO-COMPONENT (2K) CURABLE ADHESIVE COMPOSITION HENKEL AG & CO. KGAA (DE) 2025-11-06 WO claimed
WO-2025228674-A1 ELECTROCHEMICALLY DEBONDABLE ADHESIVE FILM HENKEL AG & CO. KGAA (DE) 2025-11-06 WO claimed
EP-4644502-A1 ELECTROCHEMICALLY DEBONDABLE ADHESIVE FILM Henkel AG & Co. KGaA (DE) 2025-11-05 EP claimed
US-6410799-B1 LIQUID PHASE HEATING INSTITUT FRANCAIS DU PETROLE (FR) 2002-06-25 US claimed
US-20020035297-A1 Hydroformylation process employing a catalyst based on cobalt and/or rhodium in a non-aqueous ionic solvent INSTITUT FRANCAIS DU PETROLE (FR) 2002-03-21 US claimed
US-20010039363-A1 Process for hydroformylation using a catalyst based on cobalt and/or rhodium employed in a two-phase medium INSTITUT FRANCAIS DU PETROLE (FR) 2001-11-08 US claimed
EP-0748785-B1 Process for moving the double bound in olefins using a catalytic composition comprising transition metal complexes INST FRANCAIS DU PETROLE (FR) 2000-05-31 EP claimed
US-6040263-A Catalytic composition based on transition metal complexes, and a process for the hydrogenation of unsaturated compounds INSTITUT FRANCAIS DU PETROLE (FR) 2000-03-21 US claimed
EP-0776880-B1 Process for the hydroformylation of olefinic compounds INST FRANCAIS DU PETROLE (FR) 2000-02-16 EP claimed
EP-0748653-B1 New catalytic composition containing transition metals complexes and insatured compounds hydrogenation process INST FRANCAIS DU PETROLE (FR) 2000-01-26 EP claimed
US-5874638-A Process for hydroformylation of olefinic compounds INSTITUT FRANCAIS DU PETROLE (FR) 1999-02-23 US claimed
US-5852130-A Catalytic composition based on transition metal complexes, and a process for the hydrogenation of unsaturated compounds INSTITUT FRANCAIS DU PETROLE (FR) 1998-12-22 US claimed
US-5780702-A Process for displacing the double bond in olefins using a catalytic composition based on transition metal complexes INSTITUT FRANCAIS DU PETROLE (FR) 1998-07-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035297-A1 Hydroformylation process employing a catalyst based on cobalt and/or rhodium in a non-aqueous ionic solvent NUDT1, IDH1, HRH4 MEN1 3468/4885HSP90AA1 1482/4885KMT2A 1411/4885
US-12540262-B2 Two component (2K) curable adhesive composition ILK, MAT2A, MMAB MEN1 2290/4885HSP90AA1 265/4885KMT2A 512/4885
US-20260088410-A1 ELECTRONICS ASSEMBLY HAVING ELECTROCHEMICALLY DEBONDABLE COMPONENTS EPCAM, CDH1, ITGA4 MEN1 2502/4885HSP90AA1 3206/4885KMT2A 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.